

N107Q : 5' -GAACTATAACACCCAGTCCAGCCACGCTC-3'
 N231Q : 5' -CTGCCGGCACTTCCAGGACAGTGGAGCCT-3'
 N334Q : 5' -TGATGGATTTGTGCAGTGCACCAAGATCC-3'
 N389Q : 5' -GCCCCACATGCACCAGTTCAGTGTTTTTT-3'
 N395Q : 5' -CAGTGTTTTTTTCCCAGTTGACAACCATTG-3'
 N418Q : 5' -CATGAAGAAGCTTGCAGGTCACATCTCTGG-3'
 N450Q : 5' -CCACCACTCTTTGCAGTGGACCAAGGTGC-3'
 N503Q : 5' -CTTGTCCTGTCTGACAGTATAGCCGAGGAG-3'
 N547Q : 5' -CACTGCCACATGCCAGGGCTCGGGCTCTG-3'
 N597Q : 5' -GCCCTGCCATGAGCAGTGCACCCAGGGGT-3'
 V333Q : 5' -CATTGATGGATTTTCAGAACTGCACCAAGA-3'
 H388Q : 5' -GCCGCCCCACATGCAGAACTTCAGTGTTT-3'
 S394Q : 5' -CTTCAGTGTTTTTTCAGAATTTGACAACCA-3'
 L417Q : 5' -GATCATGAAGAACCAGAATGTCACATCTC-3'
 L449Q : 5' -CTACCACCACTCTCAGAACTGGACCAAGG-3'

Supplementary Table 1. To substitute the *N*-linked glycosylation sites of ErbB3, point mutations were introduced in ErbB3 using indicated primers.